KALINOR 1.56 g potassium / 2.5 g citrate effervescent tablets

Active ingredient: potassium citrate.

KALINOR potassium citrate Composition:

The active ingredient is in the effervescent tablet as potassium citrate, potassium hydrogen carbonate and citric acid after conversion: 2.17 g potassium citrate (Ph.Eur.) 2.00 g potassium hydrogen carbonate 2.057 g citric acid. Excipients with known effect: 1.42 g glucose syrup and sucrose. Note for diabetics: 1 effervescent tablet corresponds to 0.12 bread units (BU).

KALINOR potassium citrate Areas of application:

Kalinor effervescent tablets are used in adults. For potassium substitution in the case of: pronounced hypokalaemia (<3.2 mmol / l), especially in the presence of metabolic acidosis; hypokalemic neuromuscular disorders or cardiac arrhythmias; Hypokalaemia with simultaneous digitalist therapy. For prophylaxis of hypokalaemia in ketoacidosis. For kidney stone metaphylaxis in: calcium stones (eg in renal tubular acidosis); Hypocitraturia (<320 mg / d) of various origins; Uric acid stones.

KALINOR effervescent tablets 15 pc potassium citrate:

Contraindications: Hypersensitivity to potassium citrate, potassium hydrogen carbonate, citric acid or any of the other ingredients. Kalinor effervescent tablets must not be used in diseases that are often associated with hyperkalemia: dehydration, impaired excretory kidney function, Addison's disease, adynamia episodica hereditaria.

Side effects: Uncommon: heartburn, abdominal pain, diarrhea, belching, nausea / vomiting, flatulence. Rare: hyperkalemia; Allergic reactions such as: eczema, itching, rash, facial swelling. In this case, the preparation should be discontinued. Very rare: Excessive intake of potassium can lead to cardiac arrhythmias.

Pharmaceutical company
Desma GmbH Peter-Sander-Str. 41b - 55252 Mainz-Kastel